NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Forecast, Price & News $24.14 -0.41 (-1.67%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$23.50▼$24.4550-Day Range$24.55▼$31.3852-Week Range$21.04▼$34.16Volume672,073 shsAverage Volume489,993 shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$50.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SpringWorks Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.2% Upside$50.50 Price TargetShort InterestBearish23.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$70,872 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.19) to ($4.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector759th out of 965 stocksBiological Products, Except Diagnostic Industry120th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.50, SpringWorks Therapeutics has a forecasted upside of 109.2% from its current price of $24.14.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted23.22% of the outstanding shares of SpringWorks Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 24.7, which indicates bearish sentiment.Change versus previous monthShort interest in SpringWorks Therapeutics has recently decreased by 3.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 2.7 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for SpringWorks Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for SWTX on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $70,872.00 in company stock.Percentage Held by InsidersOnly 7.43% of the stock of SpringWorks Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($5.19) to ($4.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SpringWorks Therapeutics (NASDAQ:SWTX) StockSpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More SWTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Stock News HeadlinesSeptember 11, 2023 | msn.comSpringWorks Therapeutics gets new chief scientific officerSeptember 11, 2023 | markets.businessinsider.comSpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific OfficerSeptember 22, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. August 24, 2023 | markets.businessinsider.comSpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA UpdateAugust 24, 2023 | msn.comHC Wainwright & Co. Reiterates SpringWorks Therapeutics (SWTX) Buy RecommendationAugust 21, 2023 | seekingalpha.comSpringWorks down 6% on alleged violation of trial protocolsAugust 8, 2023 | msn.comHC Wainwright & Co. Maintains SpringWorks Therapeutics (SWTX) Buy RecommendationAugust 2, 2023 | finanznachrichten.deSpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsSeptember 22, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. August 2, 2023 | finance.yahoo.comSpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsJuly 20, 2023 | msn.comGoldman Sachs Maintains SpringWorks Therapeutics (SWTX) Buy RecommendationJuly 19, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)July 12, 2023 | seekingalpha.comSpringWorks Therapeutics: FDA Decision Date AheadJuly 1, 2023 | fool.comSpringWorks Therapeutics (NASDAQ: SWTX)June 28, 2023 | finance.yahoo.comGoldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 ‘Strong Buy’ Names With Solid Upside PotentialJune 7, 2023 | finance.yahoo.comSpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 7, 2023 | msn.comHC Wainwright & Co. Reiterates SpringWorks Therapeutics (SWTX) Prior RecommendationJune 6, 2023 | msn.comThe Latest Analyst Ratings for SpringWorks TherapeuticsJune 5, 2023 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)June 5, 2023 | msn.comFDA extends action deadline for SpringWorks nirogacestat drug applicationJune 5, 2023 | reuters.comUS FDA delays decision on SpringWorks Therapeutics' tumor treatmentJune 5, 2023 | markets.businessinsider.comSpringWorks: FDA Extends PDUFA Date For Nirogacestat NDAJune 5, 2023 | marketwatch.comSpringWorks Therapeutics: FDA Extends Review of Nirogacestat >SWTXJune 5, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDAMay 30, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell TumorsMay 25, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual MeetingMay 11, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 CongressSee More Headlines Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTX Company Calendar Last Earnings8/02/2023Today9/21/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees227Year Founded2017Price Target and Rating Average Stock Price Forecast$50.50 High Stock Price Forecast$66.00 Low Stock Price Forecast$41.00 Forecasted Upside/Downside+109.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-277,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.98% Return on Assets-49.69% Debt Debt-to-Equity RatioN/A Current Ratio11.55 Quick Ratio11.55 Sales & Book Value Annual Sales$35 million Price / Sales43.16 Cash FlowN/A Price / Cash FlowN/A Book Value$8.95 per share Price / Book2.70Miscellaneous Outstanding Shares62,570,000Free Float57,921,000Market Cap$1.51 billion OptionableNot Optionable Beta0.58 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Saqib Islam J.D. (Age 53)CEO & Director Comp: $1.26MMr. Francis I. Perier Jr. (Age 63)M.B.A., Chief Financial Officer Comp: $710.6kDr. Badreddin Edris Ph.D. (Age 36)Chief Operating Officer Comp: $998.61kDr. L. Mary Smith PH.D. (Age 56)Chief Devel. Officer Comp: $817.17kMr. Bhavesh Ashar (Age 57)Chief Commercial Officer Comp: $729.62kMr. Michael P. Nofi (Age 52)Chief Accounting Officer Ms. Kim DiamondVP of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)Gen. Counsel & Sec. Mr. Daniel J. Pichl (Age 40)Chief People Officer Dr. James Cassidy M.D. (Age 64)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsVericelNASDAQ:VCELArcellxNASDAQ:ACLXBioCryst PharmaceuticalsNASDAQ:BCRXRecursion PharmaceuticalsNASDAQ:RXRXIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 541,921 shares on 8/24/2023Ownership: 2.457%Comerica BankBought 4,562 shares on 8/22/2023Ownership: 0.007%Affinity Asset Advisors LLCBought 130,000 shares on 8/21/2023Ownership: 0.208%California State Teachers Retirement SystemBought 6,112 shares on 8/21/2023Ownership: 0.079%Osaic Holdings Inc.Bought 782 shares on 8/21/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions SWTX Stock - Frequently Asked Questions Should I buy or sell SpringWorks Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SWTX shares. View SWTX analyst ratings or view top-rated stocks. What is SpringWorks Therapeutics' stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month target prices for SpringWorks Therapeutics' stock. Their SWTX share price forecasts range from $41.00 to $66.00. On average, they predict the company's share price to reach $50.50 in the next year. This suggests a possible upside of 109.2% from the stock's current price. View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts. How have SWTX shares performed in 2023? SpringWorks Therapeutics' stock was trading at $26.01 at the beginning of 2023. Since then, SWTX shares have decreased by 7.2% and is now trading at $24.14. View the best growth stocks for 2023 here. When is SpringWorks Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our SWTX earnings forecast. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.01. During the same quarter in the prior year, the business earned ($1.41) EPS. What ETFs hold SpringWorks Therapeutics' stock? ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI). When did SpringWorks Therapeutics IPO? (SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is SpringWorks Therapeutics' stock symbol? SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX." Who are SpringWorks Therapeutics' major shareholders? SpringWorks Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.81%), Deep Track Capital LP (5.67%), State Street Corp (5.04%), ArrowMark Colorado Holdings LLC (3.99%), Artal Group S.A. (2.90%) and Perceptive Advisors LLC (2.46%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SpringWorks Therapeutics' stock price today? One share of SWTX stock can currently be purchased for approximately $24.14. How much money does SpringWorks Therapeutics make? SpringWorks Therapeutics (NASDAQ:SWTX) has a market capitalization of $1.51 billion and generates $35 million in revenue each year. The company earns $-277,420,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. How many employees does SpringWorks Therapeutics have? The company employs 227 workers across the globe. Does SpringWorks Therapeutics have any subsidiaries? The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..Read More How can I contact SpringWorks Therapeutics? SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The official website for the company is www.springworkstx.com. The company can be reached via phone at 203-883-9490 or via email at investors@springworkstx.com. This page (NASDAQ:SWTX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.